Draft Infection Control in Healthcare Personnel: Epidemiology and Control of Selected Infections Transmitted Among Healthcare Personnel and Patients: Diphtheria, Group A Streptococcus, Meningococcal Disease, and Pertussis Sections; Re-Opening of Comment Period, 12949-12950 [2021-04515]
Download as PDF
jbell on DSKJLSW7X2PROD with NOTICES
Federal Register / Vol. 86, No. 42 / Friday, March 5, 2021 / Notices
Specific questions of interest to the
AHRQ include, but are not limited to,
the following:
1. What clinical algorithms are used
in clinical practice, hospitals, health
systems, payment systems, or other
instances? What is the estimated impact
of these algorithms in size and
characteristics of population affected,
quality of care, clinical outcomes,
quality of life and health disparities?
2. Do the algorithms in question 1
include race/ethnicity as a variable and,
if so, how was race and ethnicity
defined (including from whose
perspective and whether there is a
designation for mixed race or
multiracial individuals)?
3. Do the algorithms in question 1
include measures of social determinants
of health (SDOH) and, if so, how were
these defined? Are these independently
or collectively examined for their
potential contribution to healthcare
disparities and biases in care?
4. For the algorithms in question 1,
what evidence, data quality and types
(such as claims/utilization data, clinical
data, social determinants of health), and
data sources were used in their
development and validation? What is
the sample size of the datasets used for
development and validation? What is
the representation of Black, Indigenous,
and People of Color (BIPOC) and what
is the power to detect between-group
differences? What methods were used to
validate the algorithms and measure
health outcomes associated with the use
of the algorithms?
5. For the algorithms in question 1,
what approaches are used in updating
these algorithms?
6. Which clinical algorithms have
evidence that they contribute to
healthcare disparities, including
decreasing access to care, quality of care
or worsening health outcomes for
BIPOC? What are the priority
populations or conditions for assessing
whether algorithms increase racial/
ethnic disparities? What are the
mechanisms by which use of algorithms
contribute to poor care for BIPOC?
7. To what extent are users of
algorithms including clinicians, health
systems, and health plans aware of the
inclusion of race/ethnicity or other
variables that could introduce bias in
these algorithms and the implications
for clinical decision making? What
evidence is available about the degree to
which the use of clinical algorithms
contributes to bias in care delivery and
resulting disparities in health outcomes?
To what extent are patients aware of the
inclusion of race/ethnicity or other
variables that can result in bias in
algorithms that influence their care? Do
VerDate Sep<11>2014
20:30 Mar 04, 2021
Jkt 253001
providers or health systems
communicate this information with
patients in ways that can be
understood?
8. What are approaches to identifying
sources of bias and/or correcting or
developing new algorithms that may be
free of bias? What evidence, data quality
and types (such as claims/utilization
data, clinical data, information on social
determinants of health), and data
sources and sample size are used in
their development and validation? What
is the impact of these new approaches
and algorithms on outcomes?
9. What challenges have arisen or can
arise by designing algorithms developed
using traditional biomedical or
physiologic factors (such as blood
glucose) yet include race/ethnicity as a
proxy for other factors such as specific
biomarkers, genetic information, etc.?
What strategies can be used to address
these challenges?
10. What are existing and developing
standards (national and international)
about how clinical algorithms should be
developed, validated, and updated in a
way to avoid bias? Are you aware of
guidance on the inclusion or race/
ethnicity, related variables such as
SDOH, prior utilization, or other
variables to minimize the risk of bias?
11. To what extent are users of
clinical algorithms educated about how
algorithms are developed or may
influence their decision-making? What
educational curricula and training is
available for clinicians that addresses
bias in clinical algorithms?
AHRQ is interested in all of the
questions listed above, but respondents
are welcome to address as many or as
few as they choose and to address
additional areas of interest not listed.
This RFI is for planning purposes
only and should not be construed as a
policy, solicitation for applications, or
as an obligation on the part of the
Government to provide support for any
ideas identified in response to it. AHRQ
will use the information submitted in
response to this RFI at its discretion and
will not provide comments to any
responder’s submission. However,
responses to the RFI may be reflected in
future solicitation(s) or policies. The
information provided will be analyzed
and may appear in reports. Respondents
will not be identified in any published
reports. Respondents are advised that
the Government is under no obligation
to acknowledge receipt of the
information received or provide
feedback to respondents with respect to
any information submitted. No
proprietary, classified, confidential, or
sensitive information should be
included in your response. The contents
PO 00000
Frm 00050
Fmt 4703
Sfmt 4703
12949
of all submissions will be made
available to the public upon request.
Materials submitted must be publicly
available or can be made public.
Dated: March 1, 2021.
Marquita Cullom,
Associate Director.
[FR Doc. 2021–04509 Filed 3–4–21; 8:45 am]
BILLING CODE 4160–90–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[Docket No. CDC–2020–0011]
Draft Infection Control in Healthcare
Personnel: Epidemiology and Control
of Selected Infections Transmitted
Among Healthcare Personnel and
Patients: Diphtheria, Group A
Streptococcus, Meningococcal
Disease, and Pertussis Sections; ReOpening of Comment Period
Centers for Disease Control and
Prevention (CDC), Department of Health
and Human Services (DHHS).
ACTION: Notice with comment.
AGENCY:
The Centers for Disease
Control and Prevention (CDC), in the
Department of Health and Human
Services (DHHS), announces the reopening of a docket to obtain a public
comment on the DRAFT Infection
Control in Healthcare Personnel:
Epidemiology and Control of Selected
Infections Transmitted Among
Healthcare Personnel and Patients:
Diphtheria, Group A Streptococcus,
Meningococcal Disease, and Pertussis
Sections (‘‘Draft Guideline’’).
DATES: Written comments must be
received on or before May 4, 2021.
ADDRESSES: You may submit comments,
identified by Docket No. CDC–2020–
0011, by any of the following methods:
• Federal eRulemaking Portal: https://
www.regulations.gov. Follow the
instructions for submitting comments.
• Mail: Division of Healthcare Quality
Promotion, National Center for
Emerging and Zoonotic Infectious
Diseases, Centers for Disease Control
and Prevention, Attn: Docket No. CDC–
2020–0011, Infection Prevention and
Control Guidelines, 1600 Clifton Rd.
NE, Mailstop H16–2, Atlanta, Georgia,
30329.
Instructions: All submissions received
must include the agency name and
Docket Number. All relevant comments
received will be posted without change
to https://regulations.gov, including any
personal information provided. For
SUMMARY:
E:\FR\FM\05MRN1.SGM
05MRN1
12950
Federal Register / Vol. 86, No. 42 / Friday, March 5, 2021 / Notices
access to the docket to read background
documents or comments received, go to
https://www.regulations.gov.
FOR FURTHER INFORMATION CONTACT: Erin
Stone, M.A., Division of Healthcare
Quality Promotion, National Center for
Emerging and Zoonotic Infectious
Diseases, Centers for Disease Control
and Prevention, 1600 Clifton Road NE,
Mailstop H16–2, Atlanta, Georgia,
30329; Email: IPCGuidelines@cdc.gov;
Telephone: (404) 639–4000.
SUPPLEMENTARY INFORMATION:
Public Participation
Interested persons or organizations
are invited to participate by submitting
written views, recommendations, and
data related to the Draft Guideline.
Please note that comments received,
including attachments and other
supporting materials, are part of the
public record and are subject to public
disclosure. Comments will be posted on
https://www.regulations.gov. Therefore,
do not include any information in your
comment or supporting materials that
you consider confidential or
inappropriate for public disclosure. If
you include your name, contact
information, or other information that
identifies you in the body of your
comments, that information will be on
public display. CDC will review all
submissions and may choose to redact,
or withhold, submissions containing
private or proprietary information such
as Social Security numbers, medical
information, inappropriate language, or
duplicate/near duplicate examples of a
mass-mail campaign. CDC will carefully
consider all comments submitted in
preparation of the final Infection Control
in Healthcare Personnel: Epidemiology
and Control of Selected Infections
Transmitted Among Healthcare
Personnel and Patients and may revise
the Draft Guideline as appropriate.
Background
jbell on DSKJLSW7X2PROD with NOTICES
On February 26, 2020, CDC published
a notice in the Federal Register
requesting public comment on the ‘Draft
Infection Control in Healthcare
Personnel: Epidemiology and Control of
Selected Infections Transmitted Among
Healthcare Personnel and Patients:
Diphtheria, Group A Streptococcus,
Meningococcal Disease, and Pertussis
Sections’ (85 FR 11084). Because the
original notice was published in the
early days of the COVID–19 pandemic,
interested persons may not have had the
opportunity to provide comment. For
this reason, CDC has decided to re-open
the comment period to provide the
public with additional time to review
the draft document and provide
comment.
The Draft Guideline updates four
sections of the Guideline for Infection
Control in Health Care Personnel, 1998
(‘‘1998 Guideline’’), Part E:
Epidemiology and Control of Selected
Infections Transmitted Among Health
Care Personnel and Patients, and their
corresponding recommendations in Part
II of the 1998 Guideline: ‘‘4.
Diphtheria;’’ ‘‘9. Meningococcal
Disease;’’ ‘‘12. Pertussis;’’ and ‘‘18.
Streptococcus, group A infection.’’ The
updated recommendations in the Draft
Guideline are intended for use by the
leaders and staff of Occupational Health
Services (OHS) to facilitate providing
occupational infection prevention and
control (IPC) services to healthcare
personnel (HCP) for the management of
exposed or infected HCP who may be
contagious to others in the workplace.
Since 2015, the Healthcare Infection
Control Practices Advisory Committee
(HICPAC) has worked with national
partners, academicians, public health
professionals, healthcare providers, and
other partners to develop this Draft
Guideline as a recommendation for CDC
to update sections of the 1998
Guideline. HICPAC includes
representatives from public health,
infectious diseases, regulatory and other
federal agencies, professional societies,
and other stakeholders.
The updated draft recommendations
in this Draft Guideline are informed by
reviews of the 1998 Guideline; current
CDC resources, guidance, and
guidelines; and new resources and
evidence, when available. This Draft
Guideline and the updated final
Guideline will not be a federal rule or
regulation.
Dated: March 1, 2021.
Sandra Cashman,
Executive Secretary, Centers for Disease
Control and Prevention.
[FR Doc. 2021–04515 Filed 3–4–21; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2021–N–0033]
Morton Grove Pharmaceuticals Inc. et
al.; Withdrawal of Approval of Seven
Abbreviated New Drug Applications
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug
Administration (FDA or Agency) is
withdrawing approval of seven
abbreviated new drug applications
(ANDAs) from multiple applicants. The
applicants notified the Agency in
writing that the drug products were no
longer marketed and requested that the
approval of the applications be
withdrawn.
SUMMARY:
Approval is withdrawn as of
April 5, 2021.
FOR FURTHER INFORMATION CONTACT:
Martha Nguyen, Center for Drug
Evaluation and Research, Food and
Drug Administration, 10903 New
Hampshire Ave., Bldg. 75, Rm. 1676,
Silver Spring, MD 20993–0002, 240–
402–6980, Martha.Nguyen@fda.hhs.gov.
SUPPLEMENTARY INFORMATION: The
applicants listed in the table have
informed FDA that these drug products
are no longer marketed and have
requested that FDA withdraw approval
of the applications under the process
described in § 314.150(c) (21 CFR
314.150(c)). The applicants have also,
by their requests, waived their
opportunity for a hearing. Withdrawal
of approval of an application or
abbreviated application under
§ 314.150(c) is without prejudice to
refiling.
DATES:
Application No.
Drug
Applicant
ANDA 065428 ........
Cefprozil Tablets, 250 milligrams (mg) and 500 mg .............
ANDA 077699 ........
Mefloquine Hydrochloride (HCl) Tablets, 250 mg .................
ANDA 078383 ........
Pioglitazone HCl Tablets, Equivalent to (EQ) 15 mg base;
EQ 30 mg base; EQ 45 mg base.
Irinotecan HCl Injection, 40 mg/2 milliliters (mL) (20 mg/mL)
and 100 mg/5 mL (20 mg/mL).
Alendronate Sodium Tablets, EQ 5 mg base; EQ 10 mg
base; EQ 35 mg base; EQ 70 mg base.
Morton Grove Pharmaceuticals Inc./Wockhardt USA LLC.,
6451 Main St., Morton Grove, IL 60053.
Hikma Pharmaceuticals USA Inc., 1809 Wilson Rd., Columbus, OH 43228.
Neopharma Inc., 211 College Road East, Suite 101, Princeton, NJ 08540.
Do.
ANDA 078953 ........
ANDA 079049 ........
VerDate Sep<11>2014
20:30 Mar 04, 2021
Jkt 253001
PO 00000
Frm 00051
Fmt 4703
Sfmt 4703
Do.
E:\FR\FM\05MRN1.SGM
05MRN1
Agencies
[Federal Register Volume 86, Number 42 (Friday, March 5, 2021)]
[Notices]
[Pages 12949-12950]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-04515]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
[Docket No. CDC-2020-0011]
Draft Infection Control in Healthcare Personnel: Epidemiology and
Control of Selected Infections Transmitted Among Healthcare Personnel
and Patients: Diphtheria, Group A Streptococcus, Meningococcal Disease,
and Pertussis Sections; Re-Opening of Comment Period
AGENCY: Centers for Disease Control and Prevention (CDC), Department of
Health and Human Services (DHHS).
ACTION: Notice with comment.
-----------------------------------------------------------------------
SUMMARY: The Centers for Disease Control and Prevention (CDC), in the
Department of Health and Human Services (DHHS), announces the re-
opening of a docket to obtain a public comment on the DRAFT Infection
Control in Healthcare Personnel: Epidemiology and Control of Selected
Infections Transmitted Among Healthcare Personnel and Patients:
Diphtheria, Group A Streptococcus, Meningococcal Disease, and Pertussis
Sections (``Draft Guideline'').
DATES: Written comments must be received on or before May 4, 2021.
ADDRESSES: You may submit comments, identified by Docket No. CDC-2020-
0011, by any of the following methods:
Federal eRulemaking Portal: https://www.regulations.gov.
Follow the instructions for submitting comments.
Mail: Division of Healthcare Quality Promotion, National
Center for Emerging and Zoonotic Infectious Diseases, Centers for
Disease Control and Prevention, Attn: Docket No. CDC-2020-0011,
Infection Prevention and Control Guidelines, 1600 Clifton Rd. NE,
Mailstop H16-2, Atlanta, Georgia, 30329.
Instructions: All submissions received must include the agency name
and Docket Number. All relevant comments received will be posted
without change to https://regulations.gov, including any personal
information provided. For
[[Page 12950]]
access to the docket to read background documents or comments received,
go to https://www.regulations.gov.
FOR FURTHER INFORMATION CONTACT: Erin Stone, M.A., Division of
Healthcare Quality Promotion, National Center for Emerging and Zoonotic
Infectious Diseases, Centers for Disease Control and Prevention, 1600
Clifton Road NE, Mailstop H16-2, Atlanta, Georgia, 30329; Email:
[email protected]; Telephone: (404) 639-4000.
SUPPLEMENTARY INFORMATION:
Public Participation
Interested persons or organizations are invited to participate by
submitting written views, recommendations, and data related to the
Draft Guideline.
Please note that comments received, including attachments and other
supporting materials, are part of the public record and are subject to
public disclosure. Comments will be posted on https://www.regulations.gov. Therefore, do not include any information in your
comment or supporting materials that you consider confidential or
inappropriate for public disclosure. If you include your name, contact
information, or other information that identifies you in the body of
your comments, that information will be on public display. CDC will
review all submissions and may choose to redact, or withhold,
submissions containing private or proprietary information such as
Social Security numbers, medical information, inappropriate language,
or duplicate/near duplicate examples of a mass-mail campaign. CDC will
carefully consider all comments submitted in preparation of the final
Infection Control in Healthcare Personnel: Epidemiology and Control of
Selected Infections Transmitted Among Healthcare Personnel and Patients
and may revise the Draft Guideline as appropriate.
Background
On February 26, 2020, CDC published a notice in the Federal
Register requesting public comment on the `Draft Infection Control in
Healthcare Personnel: Epidemiology and Control of Selected Infections
Transmitted Among Healthcare Personnel and Patients: Diphtheria, Group
A Streptococcus, Meningococcal Disease, and Pertussis Sections' (85 FR
11084). Because the original notice was published in the early days of
the COVID-19 pandemic, interested persons may not have had the
opportunity to provide comment. For this reason, CDC has decided to re-
open the comment period to provide the public with additional time to
review the draft document and provide comment.
The Draft Guideline updates four sections of the Guideline for
Infection Control in Health Care Personnel, 1998 (``1998 Guideline''),
Part E: Epidemiology and Control of Selected Infections Transmitted
Among Health Care Personnel and Patients, and their corresponding
recommendations in Part II of the 1998 Guideline: ``4. Diphtheria;''
``9. Meningococcal Disease;'' ``12. Pertussis;'' and ``18.
Streptococcus, group A infection.'' The updated recommendations in the
Draft Guideline are intended for use by the leaders and staff of
Occupational Health Services (OHS) to facilitate providing occupational
infection prevention and control (IPC) services to healthcare personnel
(HCP) for the management of exposed or infected HCP who may be
contagious to others in the workplace.
Since 2015, the Healthcare Infection Control Practices Advisory
Committee (HICPAC) has worked with national partners, academicians,
public health professionals, healthcare providers, and other partners
to develop this Draft Guideline as a recommendation for CDC to update
sections of the 1998 Guideline. HICPAC includes representatives from
public health, infectious diseases, regulatory and other federal
agencies, professional societies, and other stakeholders.
The updated draft recommendations in this Draft Guideline are
informed by reviews of the 1998 Guideline; current CDC resources,
guidance, and guidelines; and new resources and evidence, when
available. This Draft Guideline and the updated final Guideline will
not be a federal rule or regulation.
Dated: March 1, 2021.
Sandra Cashman,
Executive Secretary, Centers for Disease Control and Prevention.
[FR Doc. 2021-04515 Filed 3-4-21; 8:45 am]
BILLING CODE 4163-18-P